Literature DB >> 29131884

Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease.

Shahd H M Hamid1, Dan Whittam1, Mariyam Saviour2, Amal Alorainy3, Kerry Mutch1, Samantha Linaker1, Tom Solomon4, Maneesh Bhojak1, Mark Woodhall5, Patrick Waters5, Richard Appleton6, Martin Duddy7, Anu Jacob1.   

Abstract

Importance: Antibodies to myelin oligodendrocyte glycoprotein IgG (MOG-IgG) are increasingly detected in patients with non-multiple sclerosis-related demyelination, some of whom manifest a neuromyelitis optica (NMO) phenotype. Cortical involvement, encephalopathy, and seizures are rare in aquaporin 4 antibody (AQP4-IgG)-related NMO in the white European population. However, the authors encountered several patients with seizures associated with MOG-IgG disease. Objective: To compare incidence of seizures and encephalitis-like presentation, or both between AQP4-IgG-positive and MOG-IgG-positive patients. Design, Setting, and Participants: Retrospective case series of all patients who were seropositive for MOG-IgG (n = 34) and the last 100 patients with AQP4-IgG disease (NMO spectrum disorder) seen in the NMO service between January 2013 and December 2016, and analysis was completed January 4, 2017. All patients were seen in a tertiary neurological center, The Walton Centre NHS Foundation Trust in Liverpool, England. Main Outcomes and Measures: The difference in seizure frequency between the AQP4-IgG-positive and MOG-IgG-positive patient groups was determined.
Results: Thirty-four patients with MOG-IgG disease (20 female) with a median age at analysis of 30.5 years (interquartile range [IQR], 15-69 years), and 100 AQP4-IgG-positive patients (86 female) with a median age at analysis of 54 years (IQR, 12-91 years) were studied. Most patients were of white race. Five of the 34 patients with MOG-IgG (14.7%) had seizures compared with 1 patient with AQP4-IgG (2-sided P < .008, Fisher test). On magnetic resonance imaging, all 5 MOG-IgG-positive patients had inflammatory cortical brain lesions associated with the seizures. In 3 of the 5 MOG-IgG-positive patients, seizures occurred as part of the index event. Four of the 5 presented with encephalopathy and seizures, and disease relapsed in all 5 patients. Four of these patients were receiving immunosuppressant medication at last follow-up, and 3 continued to take antiepileptic medication. In contrast, the only AQP4-IgG-positive patient with seizures had a diagnosis of complex partial epilepsy preceding the onset of NMO by several years and experienced no encephalitic illness; her magnetic resonance imaging results demonstrated no cortical, subcortical, or basal ganglia involvement. Conclusions and Relevance: Patients with MOG-IgG-associated disease were more likely to have seizures and encephalitis-like presentation than patients with AQP4-IgG-associated disease.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29131884      PMCID: PMC5833490          DOI: 10.1001/jamaneurol.2017.3196

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  23 in total

1.  Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.

Authors:  P J Waters; A McKeon; M I Leite; S Rajasekharan; V A Lennon; A Villalobos; J Palace; J N Mandrekar; A Vincent; A Bar-Or; S J Pittock
Journal:  Neurology       Date:  2012-02-01       Impact factor: 9.910

2.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.

Authors:  Sven Jarius; Klemens Ruprecht; Ingo Kleiter; Nadja Borisow; Nasrin Asgari; Kalliopi Pitarokoili; Florence Pache; Oliver Stich; Lena-Alexandra Beume; Martin W Hümmert; Marius Ringelstein; Corinna Trebst; Alexander Winkelmann; Alexander Schwarz; Mathias Buttmann; Hanna Zimmermann; Joseph Kuchling; Diego Franciotta; Marco Capobianco; Eberhard Siebert; Carsten Lukas; Mirjam Korporal-Kuhnke; Jürgen Haas; Kai Fechner; Alexander U Brandt; Kathrin Schanda; Orhan Aktas; Friedemann Paul; Markus Reindl; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2016-09-27       Impact factor: 8.322

3.  An Adult Case of Anti-Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Multiphasic Acute Disseminated Encephalomyelitis at 33-year Intervals.

Authors:  Soichiro Numa; Takashi Kasai; Takayuki Kondo; Yukie Kushimura; Ayaka Kimura; Hisashi Takahashi; Kanako Morita; Akihiro Tanaka; Yu-Ichi Noto; Tomoyuki Ohara; Masanori Nakagawa; Toshiki Mizuno
Journal:  Intern Med       Date:  2016-03-15       Impact factor: 1.271

4.  Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.

Authors:  Joanna Kitley; Mark Woodhall; Patrick Waters; M Isabel Leite; Emma Devenney; John Craig; Jacqueline Palace; Angela Vincent
Journal:  Neurology       Date:  2012-08-22       Impact factor: 9.910

5.  Spectrum of pediatric neuromyelitis optica.

Authors:  Timothy E Lotze; Jennifer L Northrop; George J Hutton; Benjamin Ross; Jade S Schiffman; Jill V Hunter
Journal:  Pediatrics       Date:  2008-10-06       Impact factor: 7.124

Review 6.  Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination.

Authors:  Sudarshini Ramanathan; Russell C Dale; Fabienne Brilot
Journal:  Autoimmun Rev       Date:  2015-12-17       Impact factor: 9.754

7.  Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children.

Authors:  Yael Hacohen; Michael Absoud; Kumaran Deiva; Cheryl Hemingway; Petra Nytrova; Mark Woodhall; Jacqueline Palace; Evangeline Wassmer; Marc Tardieu; Angela Vincent; Ming Lim; Patrick Waters
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-03-12

8.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Authors:  Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker
Journal:  Neurology       Date:  2015-06-19       Impact factor: 9.910

9.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.

Authors:  Sven Jarius; Ingo Kleiter; Klemens Ruprecht; Nasrin Asgari; Kalliopi Pitarokoili; Nadja Borisow; Martin W Hümmert; Corinna Trebst; Florence Pache; Alexander Winkelmann; Lena-Alexandra Beume; Marius Ringelstein; Oliver Stich; Orhan Aktas; Mirjam Korporal-Kuhnke; Alexander Schwarz; Carsten Lukas; Jürgen Haas; Kai Fechner; Mathias Buttmann; Judith Bellmann-Strobl; Hanna Zimmermann; Alexander U Brandt; Diego Franciotta; Kathrin Schanda; Friedemann Paul; Markus Reindl; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2016-11-01       Impact factor: 8.322

10.  NMDA receptor antibodies: A rare association in inflammatory demyelinating diseases.

Authors:  Melanie Ramberger; Gabriel Bsteh; Kathrin Schanda; Romana Höftberger; Kevin Rostásy; Matthias Baumann; Fahmy Aboulenein-Djamshidian; Andreas Lutterotti; Florian Deisenhammer; Thomas Berger; Markus Reindl
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-08-13
View more
  61 in total

1.  Bilateral trigeminal root entry zone enhancement in MOG-IgG-associated brainstem encephalitis.

Authors:  Yaoyao Shen; Zhijuan Cheng; Chenguang Zhou
Journal:  Neurol Sci       Date:  2018-12-05       Impact factor: 3.307

Review 2.  Autoimmune seizures and epilepsy.

Authors:  Christian Geis; Jesus Planagumà; Mar Carreño; Francesc Graus; Josep Dalmau
Journal:  J Clin Invest       Date:  2019-02-04       Impact factor: 14.808

Review 3.  Detection of MOG-IgG by cell-based assay: moving from discovery to clinical practice.

Authors:  Amanda Marchionatti; Mark Woodhall; Patrick Joseph Waters; Douglas Kazutoshi Sato
Journal:  Neurol Sci       Date:  2020-10-15       Impact factor: 3.307

4.  Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders.

Authors:  Liqin Yang; Haiqing Li; Wei Xia; Chao Quan; Lei Zhou; Daoying Geng; Yuxin Li
Journal:  Eur Radiol       Date:  2019-11-20       Impact factor: 5.315

5.  Myelin Oligodendrocyte Glycoprotein-IgG Contributes to Oligodendrocytopathy in the Presence of Complement, Distinct from Astrocytopathy Induced by AQP4-IgG.

Authors:  Ling Fang; Xinmei Kang; Zhen Wang; Shisi Wang; Jingqi Wang; Yifan Zhou; Chen Chen; Xiaobo Sun; Yaping Yan; Allan G Kermode; Lisheng Peng; Wei Qiu
Journal:  Neurosci Bull       Date:  2019-04-30       Impact factor: 5.203

6.  Treatment of MOG antibody associated disorders: results of an international survey.

Authors:  D H Whittam; V Karthikeayan; E Gibbons; R Kneen; S Chandratre; O Ciccarelli; Y Hacohen; J de Seze; K Deiva; R Q Hintzen; B Wildemann; S Jarius; I Kleiter; K Rostasy; P Huppke; B Hemmer; F Paul; O Aktas; A K Pröbstel; G Arrambide; M Tintore; M P Amato; M Nosadini; M M Mancardi; M Capobianco; Z Illes; A Siva; A Altintas; G Akman-Demir; L Pandit; M Apiwattankul; J Y Hor; S Viswanathan; W Qiu; H J Kim; I Nakashima; K Fujihara; S Ramanathan; R C Dale; M Boggild; S Broadley; M A Lana-Peixoto; D K Sato; S Tenembaum; P Cabre; D M Wingerchuk; B G Weinshenker; B Greenberg; M Matiello; E C Klawiter; J L Bennett; A I Wallach; I Kister; B L Banwell; A Traboulsee; D Pohl; J Palace; M I Leite; M Levy; R Marignier; T Solomon; M Lim; S Huda; A Jacob
Journal:  J Neurol       Date:  2020-07-04       Impact factor: 4.849

7.  Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease.

Authors:  Sara Salama; Majid Khan; Michael Levy; Izlem Izbudak
Journal:  Mult Scler Relat Disord       Date:  2019-01-10       Impact factor: 4.339

8.  Clinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorder.

Authors:  Sara Salama; Santiago Pardo; Michael Levy
Journal:  Mult Scler Relat Disord       Date:  2019-02-22       Impact factor: 4.339

Review 9.  Neuromyelitis optica spectrum disorders and pregnancy: relapse-preventive measures and personalized treatment strategies.

Authors:  Nadja Borisow; Kerstin Hellwig; Friedemann Paul
Journal:  EPMA J       Date:  2018-08-10       Impact factor: 6.543

10.  Autoimmune cortical encephalitis in two children with anti-myelin oligodendrocyte glycoprotein (MOG) antibody.

Authors:  D Doig; C McNamara; L Mewasingh; S Beri; B Jones; C Kachramanoglou; W Jan
Journal:  J Neurol       Date:  2020-10-14       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.